Life Science News

Amgen today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance issues. Amgen also was named to the DJSI North America Index for the ninth straight year. The DJSI Indices are among the best indicators of a company's ESG performance due to the breadth of companies evaluated ...

Amgen (NASDAQ:AMGN) today announced that it has been named to the Dow Jones Sustainability World Index for the eighth consecutive year, reflecting the company's enduring commitment to environmental, social, and governance (ESG) issues. Amgen also was named to the DJSI North America Index for the ninth straight year.

The DJSI Indices are among the best indicators of a company's ESG performance due to the breadth of companies evaluated – nearly 11,000 this year – and the rigorous nature of the annual assessment process. The DJSI World Index recognizes the top 10% of companies in the S&P Global Broad Market Index for performance on ESG issues, which S&P Global considers critical to generating long-term stakeholder value.

"Our mission is to serve patients and our ESG framework guides how we go about successfully accomplishing that mission," said Judy Brown , senior vice president, Corporate Affairs. "As we look to the future, we will continue to do our part to build a better, healthier world by addressing the challenges facing society that matter most to our business and to our stakeholders."

Amgen's four ESG pillars – Healthy People, Healthy Society, Healthy Environment and a Healthy Amgen – include commitments to:

  • Achieve carbon neutrality by 2027, along with a 40% reduction in water used and a 75% reduction in waste disposed. 1
  • Improve the diversity of its workforce as well as the diversity of patients participating in clinical trials of potential new Amgen medicines.
  • Provide employees with enhanced mental health support, including programs focused on communities of color, as well on the pandemic-related challenges facing parents.
  • Double its spend with diverse suppliers in the U.S. and triple its spend with Black-owned businesses by 2023.
  • Inspire the next generation of innovators through science education programs sponsored by the Amgen Foundation 2 that will reach nearly 24 million students worldwide this year.
  • Help those who are unable to afford the medicines they need through the Amgen Safety Net Foundation 3 , which has provided approximately $6 billion 4 of our medicines at no cost over the past five years to qualifying patients.

"We congratulate Amgen for being included in the Dow Jones Sustainability Index for DJSI World and DJSI North America," said Manjit Jus , Global Head of ESG Research, S&P Global. "A DJSI distinction is a reflection of being a sustainability leader in your industry. The record number of companies participating in the 2021 S&P Global Corporate Sustainability Assessment is testament to the growing movement for ESG disclosure and transparency."

In May 2021 , Amgen published a comprehensive Environmental, Social, and Governance Report, which is available here .

About Amgen

Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.

Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index.  In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's .

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen .

CONTACT: Amgen, Thousand Oaks

Trish Rowland , 805-447-5631 (Media)
Megan Fox , 805-447-1423 (Media)
Arvind Sood , 805-447-1060 (Investors)

  1. Represents reductions against established baselines, taking into account only verified reduction projects, and does not take into account changes associated with contraction or expansion of the company.
  2. Amgen Foundation is a separate legal entity funded solely by Amgen.
  3. Amgen Safety Net Foundation is a separate legal entity entirely funded by Amgen.
  4. Valued at wholesale acquisition cost.

View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-named-to-dow-jones-sustainability-world-index-for-eighth-consecutive-year-301433211.html

SOURCE Amgen

News Provided by PR Newswire via QuoteMedia

Bristol Myers Squibb Receives Positive CHMP Opinion for CAR T Cell Therapy Breyanzi for Relapsed or Refractory DLBCL, PMBCL and FL3B

Recommendation for approval based on results from TRANSCEND NHL 001, the largest pivotal trial of patients with large B-cell lymphoma after at least two prior therapies, and TRANSCEND WORLD

Bristol Myers Squibb (NYSE: BMY) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy. The CHMP recommendation will now be reviewed by the European Commission (EC), which has the authority to approve medicines for the European Union (EU).

Keep reading... Show less
Komo Plant Based Foods Introduces Komo Plant-Based Desserts Line

Komo Plant Based Foods Introduces Komo Plant-Based Desserts Line

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce the launch of new products as part of its plant-based desserts line. This week Komo launched three variations of a vegan and gluten-free cheesecake made with cultured coconut yogurt (from Yoggu Foods) and Cashew with an oat crust, which include a Vanilla Cheezecake, a Mango Cheezecake and a Strawberry Cheezecake

A picture containing text, food, dessertDescription automatically generated

Since September 2021, Komo has been developing the cheezecakes in its research and development test kitchen. Each product developed by Komo uses 100% plant-based and wholesome ingredients to create premium comfort favourites that make plant-based eating easy yet ultimately satisfying.

Keep reading... Show less

Top 5 Life Science ETFs (Updated January 2022)

Taking a position in a life science-focused exchange-traded fund (ETF) provides exposure to biotech and pharma companies while mitigating the risks of holding shares in a single company.

Life science ETFs achieve this diversification by tracking a basket of biotechnology and pharmaceutical stocks in the healthcare sector under one umbrella. ETF managers often narrow down the focus of the ETFs even further to follow a specific aspect of the market, and they typically adjust the weight of its holdings to match movements in the industry and give investors the best possible returns.

There are many options when it comes to life science ETFs, and to help investors understand their options, the Investing News Network has listed the top-performing life science ETFs over the past year.

Keep reading... Show less
BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

BioHarvest Sciences Inc. Projects 2022 Revenue to Grow 2.5X-3.5X to a Range of USD $5M-$7M

  • 2022 Revenue will include sales of VINIA® and Cannabis, both with high gross margins
  • Major investments in the BioFarming platform and Intellectual property
  • New patent application covers a 700% increase in Bioreactor production output

BioHarvest Sciences Inc. (CSE: BHSC) ("BioHarvest" or "the Company") announces that following the successful over-delivery of revenue targets versus guidance provided in 2021, the Company is estimating 2022 revenue to be between USD $5M-$7M, representing a significant growth of 2.5X-3.5X over 2021. The range in guidance is due to two primary determinants; the speed in which the biological technology transfer to its new 20 Tonyear facility is completed, and regulatory timelines influencing the conversion of the existing 2 Tonsyear facility from VINIA to the production of Cannabis.

The Company is also projecting to achieve break-even cash flow in 2023, when the business reaches its first scaling point. For 2022, BioHarvest plans to continue to invest heavily in R&D (as a percentage of total revenue) and in the building of manufacturing capacity for its Cannabis vertical in Israel and abroad.

Keep reading... Show less

Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine

-- Enrolled Patients in These Studies May Continue Receiving Study Medicine --

-- Studies Outside of Combination with Azacitidine Unaffected --

Keep reading... Show less
Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods to be Available for Online Purchase Across the United States through GTFO It's Vegan

Komo Plant Based Foods Inc. (CSE:YUM)(OTCQB:KOMOF)(FRA:9HB) ("Komo"), a premium plant-based food company, is pleased to announce that it will soon be available for order online throughout the United States through GTFO It's Vegan, a progressive online vegan market serving consumers across the U.S

Komo received a purchase order from GTFO and plans to ship its first pallet of Komo plant-based comfort foods to GTFO headquarters in California this week. Consumers across the United States will soon be able to order, for home delivery, all of Komo's frozen products online at GTFO It's Vegan.

Keep reading... Show less

Latest Press Releases

Related News

×